Word

Status

Pending

Status Code

688

Status Date

Tuesday, March 26, 2024

Serial Number

97331599

Mark Type

2000

Filing Date

Friday, March 25, 2022

Published for Opposition

Tuesday, January 30, 2024

Trademark Owner History

The Board of Regents of the University of Texas System - Owner At Publication

Classifications

41 (Based on Intent to Use) Educational services, namely, conducting programs, seminars, lectures and workshops in the fields of science and medicine relating to immunobiology, immunotherapy, wellness, cancer, diseases, and disease prevention and management; educational services, namely, developing and disseminating educational materials for others in the fields of science and medicine relating to immunobiology, immunotherapy, wellness, cancer, diseases, and disease prevention and management; arranging and conducting of training courses concerning research and development in the fields of cancer, autoimmune diseases, immunobiology and immunotherapy

36 (Based on Use in Commerce) Charitable fundraising services

35 (Based on Intent to Use) Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease

45 (Based on Intent to Use) Providing patient advocate services in the treatment of diseases and disorders utilizing immunotherapy

44 (Based on Intent to Use) Medical services; Dispensing of pharmaceuticals; Medical and pharmaceutical consultation; Medical services relating to cancer; Dispensing of pharmaceuticals relating to cancer; immunobiology and immunotherapy medical services; medical services, namely, the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, medical counseling; medical consulting services, namely, consulting on the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, and patient care management; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy and advisory services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, medical diagnostic testing, monitoring and reporting services; providing information on health care via a telephone and the internet; providing information on cancer treatment; medical services, namely, treatment in the field of oncology and related health problems and diseases; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment; medical analysis services, namely, analysis of tumors, cancer or equivalent medical conditions

42 (Based on Use in Commerce) Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the fields of immunobiology, immunotherapy, antibodies, and oncology research, development, testing, analysis and data; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; pharmaceutical research services; pharmaceutical research services relating to cancer

The mark consists of a solid red circle with a solid dark grey square intersecting it at the upper left corner, a solid light grey square intersecting it at the upper right corner, and a dark grey square outline intersecting it at the lower right corner, and in the background, a red square outline surrounds the red circle and light grey square with the solid dark grey square and dark grey square outline extending beyond the borders of the red square outline. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
The color(s) red and grey is/are claimed as a feature of the mark.

Trademark Events

Mar 26, 2024

Noa E-Mailed - Sou Required From Applicant

Jan 30, 2024

Official Gazette Publication Confirmation E-Mailed

Jan 30, 2024

Published For Opposition

Jan 10, 2024

Notification Of Notice Of Publication E-Mailed

Dec 28, 2023

Approved For Pub - Principal Register

Dec 4, 2023

Teas/Email Correspondence Entered

Dec 4, 2023

Correspondence Received In Law Office

Dec 4, 2023

Assigned To Lie

Jun 29, 2023

Teas Response To Office Action Received

Apr 3, 2023

Notification Of Non-Final Action E-Mailed

Apr 3, 2023

Non-Final Action E-Mailed

Apr 3, 2023

Non-Final Action Written

Feb 28, 2023

Teas/Email Correspondence Entered

Feb 28, 2023

Correspondence Received In Law Office

Feb 28, 2023

Teas Response To Office Action Received

Aug 29, 2022

Notification Of Non-Final Action E-Mailed

Aug 29, 2022

Non-Final Action E-Mailed

Aug 29, 2022

Non-Final Action Written

Aug 25, 2022

Assigned To Examiner

Apr 1, 2022

Notice Of Design Search Code E-Mailed

Mar 31, 2022

New Application Office Supplied Data Entered

Mar 29, 2022

New Application Entered